Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$74.88 USD

74.88
686,225

+1.34 (1.82%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Globus Medical (GMED) Tops Q4 Earnings Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 7.27% and 0.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Q4 Earnings and Revenues Surpass Estimates

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 274.75% and 1.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth

Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Steris (STE) Lags Q3 Earnings and Revenue Estimates

Steris (STE) delivered earnings and revenue surprises of -9.01% and 4.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Nevro (NVRO): Can Its 5.1% Jump Turn into More Strength?

Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why Investors Should Retain Globus Medical (GMED) Stock

Investors are optimistic about Globus Medical's (GMED) robust performance across several international markets.

Globus Medical (GMED) Global Growth Strong Despite Margin Woe

Despite continued margin declines in Japan, Globus Medical (GMED) remains positive on the progress and potential of its international business for long-term growth as it continues to reset the market in the country.

Globus Medical (GMED) Q3 Earnings Miss Estimates, EPS View Cut

Internationally, Globus Medical (GMED) reports double-digit growth in most markets, with the U.K., Australia, Brazil, India and Poland registering more than 40% growth.

Company News for Nov 10, 2022

Companies In The News Are: AKAM, AXON, GMED, SRC.

Globus Medical (GMED) Q3 Earnings Lag Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of -3.85% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 14.29% and 5.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical (GMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OrthoPediatrics (KIDS) Reports Q3 Loss, Lags Revenue Estimates

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 73.68% and 4.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Charles River's (CRL) New Launch to Boost Gene Therapy Workflow

Charles River's (CRL) latest product offering is expected to streamline the pathway to GMP AAV vector manufacturing without significant process development.

AngioDynamics (ANGO) Q1 Earnings, Revenues Lag Estimates

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2023.

Here's Why Investors Should Retain Globus Medical (GMED) For Now

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and new product introductions.

Globus Medical (GMED) Gains Market Share, Cost Woes Stay

Globus Medical (GMED) U.S. sales increase, driven by competitive rep conversions and robotic pull-through.

Globus Medical (GMED) Q2 Earnings Beat, Gross Margin Dips

Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.

Globus Medical (GMED) Q2 Earnings and Revenues Top Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 3.70% and 2%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates

ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 13.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Globus Medical (GMED) to Report a Decline in Earnings: What to Look Out for

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.